NASDAQ:CBLI - Cleveland BioLabs Stock Price, Price Target & More

$2.89 +0.05 (+1.76 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$2.84

Today's Range$2.79 - $2.97

52-Week Range$2.24 - $4.47

Volume6,580 shs

Average Volume17,183 shs

Market Capitalization$32.03 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.62

About Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company's advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CBLI

CUSIPN/A

Webwww.cbiolabs.com

Phone716-849-6810

Debt

Debt-to-Equity RatioN/A

Current Ratio4.33%

Quick Ratio4.33%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.95 million

Price / Sales16.72

Cash FlowN/A

Price / CashN/A

Book Value$0.66 per share

Price / Book4.38

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-9,700,000.00

Net Margins-498.31%

Return on Equity-104.66%

Return on Assets-83.32%

Miscellaneous

Employees19

Outstanding Shares11,280,000

How to Become a New Pot Stock Millionaire

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs (NASDAQ:CBLI) posted its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.10) EPS for the quarter. The biotechnology company earned $0.87 million during the quarter. Cleveland BioLabs had a negative net margin of 498.31% and a negative return on equity of 104.66%. View Cleveland BioLabs' Earnings History.

Who are some of Cleveland BioLabs' key competitors?

Some companies that are related to Cleveland BioLabs include Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), U.S. Stem Cell (USRM), Protalex (PRTX), Bioanalytical Systems (BASI), Oxygen Biotherapeutics (TENX), Algae.tec (ALGXY), Geovax Labs (GOVX) and Redpoint Bio (RPBC).

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:

Dr. Yakov N. Kogan Ph.D., MBA, Chief Exec. Officer and Interim Principal Financial Officer (Age 45)
Dr. Langdon L. Miller M.D., Pres and Chief Medical Officer (Age 64)
Dr. Andrei V. Gudkov Ph.D., D.Sci., Chief Scientific Officer (Age 62)
Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
Dr. Andrei Purmal Ph.D., VP of Chemistry

Has Cleveland BioLabs been receiving favorable news coverage?

Media stories about CBLI stock have trended somewhat positive on Monday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.16 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Cleveland BioLabs' major shareholders?

Cleveland BioLabs' stock is owned by many different of institutional and retail investors. Top institutional investors include ALPHA CAPITAL ANSTALT (1.77%) and ALPHA CAPITAL ANSTALT (1.77%). View Institutional Ownership Trends for Cleveland BioLabs.

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $2.89.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $32.03 million and generates $1.95 million in revenue each year. Cleveland BioLabs employs 19 workers across the globe.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

MarketBeat Community Rating for Cleveland BioLabs (CBLI)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		80 (Vote Outperform)
Underperform Votes:		61 (Vote Underperform)
Total Votes:		141

MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cleveland BioLabs (NASDAQ:CBLI) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 4/23/2016 forward)

Cleveland BioLabs (NASDAQ:CBLI) Earnings History and Estimates Chart

Earnings by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs (NASDAQ CBLI) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
3/6/2018	Q4 2017		($0.10)		$0.87 million	View	N/A
11/14/2017	Q3 2017		($0.11)		$0.30 million	View	N/A
8/14/2017	Q2 2017		($0.50)		$0.21 million	View	N/A
5/15/2017	Q1 2017		($0.15)		$0.58 million	View	N/A
2/22/2017	Q4 2016		($0.11)		$0.99 million	View	N/A
11/14/2016	Q3 2016		$0.10		$1.14 million	View	N/A
8/15/2016	Q2		($0.17)		$0.58 million	View	N/A
5/16/2016	Q116		($0.06)		$0.81 million	View	N/A
2/22/2016	Q4 2015		($0.15)		$1.27 million	View	N/A
11/5/2015	Q315		$0.31	$415.00 million	$0.50 million	View	N/A
8/12/2015	Q215		($0.72)	$562.10 million	$329.90 million	View	Listen
5/6/2015	Q115		($1.14)	$1.33 million	$0.61 million	View	N/A
2/24/2015	Q114		($1.02)	$3.87 million	$1.39 million	View	N/A
11/5/2014	Q3 2014		($1.20)		$0.42 million	View	N/A
8/7/2014	Q2 2014		($1.80)		$0.56 million	View	N/A
5/8/2014	Q1 2014	($1.00)	($1.20)	$2.86 million	$1.33 million	View	N/A
3/11/2014	Q413	($0.12)	($0.01)	$1.74 million	$3.87 million	View	N/A
11/6/2013	Q313	($0.14)	($0.09)	$1.61 million	$1.60 million	View	N/A
8/13/2013	Q2 2013	($0.16)	($0.07)	$1.48 million	$1.60 million	View	N/A
5/9/2013	Q1 2013	($0.17)	($0.22)	$1.73 million	$1.37 million	View	N/A
3/14/2013	Q4 2012	($4.20)	($2.40)			View	N/A
11/8/2012	Q312	($0.02)	($0.30)	$23.87 million		View	N/A
8/6/2012	Q2 2012	($0.80)	($4.26)			View	N/A
5/3/2012	Q1 2012	($2.80)	($3.64)			View	N/A
3/14/2012	Q4 2011	($2.60)	($2.50)			View	N/A
11/10/2011	Q3 2011	($2.80)	$0.74			View	N/A
8/15/2011	Q2 2011	($2.60)	($3.44)			View	N/A
8/16/2010	Q2 2010	($1.80)	($1.82)			View	N/A
5/14/2008	Q1 2008	($10.00)	($6.60)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cleveland BioLabs (NASDAQ:CBLI) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cleveland BioLabs (NASDAQ CBLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 3.91%

Insider Trading History for Cleveland BioLabs (NASDAQ:CBLI)

Institutional Ownership by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs (NASDAQ CBLI) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/25/2015	Randy S Saluck	Director	Buy	1,891	$3.42	$6,467.22
5/21/2013	Paul E Dicorleto	Director	Buy	6,210	$1.61	$9,998.10
5/17/2013	Randy S Saluck	Director	Buy	3,500	$1.60	$5,600.00
3/15/2013	James Antal	Director	Buy	3,700	$1.56	$5,772.00
9/21/2012	James Antal	Director	Buy	2,316	$2.60	$6,021.60

(Data available from 1/1/2013 forward)

Cleveland BioLabs (NASDAQ CBLI) News Headlines

Source:

Date	Headline
	Charles River Laboratories (CRL) and Cleveland BioLabs (CBLI) Critical Analysis www.americanbankingnews.com - April 20 at 3:34 PM
	Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Being Overpaid? finance.yahoo.com - April 17 at 4:42 PM
	Cleveland BioLabs (CBLI) Upgraded to Hold by ValuEngine www.americanbankingnews.com - April 10 at 7:51 PM
	Cleveland BioLabs, Inc: Cleveland Biolabs Announces Progress on European Marketing Authorization Application www.finanznachrichten.de - March 29 at 10:05 AM
	Cleveland Biolabs Announces Progress on European Marketing Authorization Application finance.yahoo.com - March 29 at 10:05 AM
	Cleveland Biolabs Reports 2017 Financial Results and Development Progress finance.yahoo.com - March 6 at 9:31 AM
	Reviewing Cleveland BioLabs (CBLI) & Chromadex (CDXC) www.americanbankingnews.com - February 28 at 5:08 AM
	Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors? finance.yahoo.com - February 21 at 4:32 PM
	Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc (NASDAQ:CBLI)? finance.yahoo.com - February 9 at 5:33 PM
	Critical Survey: Cleveland BioLabs (CBLI) versus Abeona Therapeutics (ABEO) www.americanbankingnews.com - January 23 at 9:30 AM
	Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Incentives Align With Yours? finance.yahoo.com - January 1 at 4:54 PM
	Cleveland BioLabs (CBLI) & Agenus (AGEN) Head-To-Head Survey www.americanbankingnews.com - January 1 at 1:22 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : December 29, 2017 finance.yahoo.com - December 29 at 4:55 PM
	Is Cleveland BioLabs Inc (NASDAQ:CBLI) As Financially Strong As Its Balance Sheet Indicates? finance.yahoo.com - December 22 at 8:07 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017 finance.yahoo.com - December 13 at 5:08 PM
	Cleveland BioLabs (CBLI) versus The Competition Critical Review www.americanbankingnews.com - December 5 at 9:26 PM
	Cleveland BioLabs (CBLI) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - December 3 at 7:58 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017 finance.yahoo.com - November 30 at 4:57 PM
	Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 finance.yahoo.com - November 29 at 10:00 AM
	What Does Cleveland BioLabs Inc’s (CBLI) Ownership Structure Look Like? finance.yahoo.com - November 22 at 10:44 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017 finance.yahoo.com - November 16 at 12:26 PM
	Cleveland BioLabs, Inc. (CBLI) Posts Quarterly Earnings Results www.americanbankingnews.com - November 15 at 12:56 PM
	Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress finance.yahoo.com - November 14 at 5:29 PM
	Financial Contrast: Cleveland BioLabs (CBLI) versus Its Peers www.americanbankingnews.com - November 13 at 11:28 AM
	How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector? finance.yahoo.com - November 8 at 7:59 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017 finance.yahoo.com - October 26 at 5:11 PM
	Head to Head Survey: Curis (CRIS) and Cleveland BioLabs (CBLI) www.americanbankingnews.com - October 13 at 8:32 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017 finance.yahoo.com - October 11 at 6:31 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017 finance.yahoo.com - September 19 at 10:01 PM
	Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 finance.yahoo.com - September 18 at 5:17 PM
	Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST) www.americanbankingnews.com - September 17 at 2:31 AM
	What You Must Know About Cleveland BioLabs Inc’s (CBLI) Risks finance.yahoo.com - September 11 at 5:34 PM
	Cleveland BioLabs, Inc. (CBLI) Posts Earnings Results www.americanbankingnews.com - August 15 at 9:41 AM
	Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential finance.yahoo.com - August 11 at 5:26 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017 finance.yahoo.com - August 4 at 10:18 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017 finance.yahoo.com - July 12 at 5:35 PM
	Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress feeds.benzinga.com - May 15 at 8:01 AM
	Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX... www.finanznachrichten.de - April 19 at 11:03 PM
	Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus investorplace.com - April 19 at 3:33 PM
	Cleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review www.streetinsider.com - April 19 at 1:01 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh biz.yahoo.com - February 22 at 9:21 PM
	Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD www.streetinsider.com - October 12 at 8:37 AM
	BRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of Defense www.reuters.com - October 11 at 4:13 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers biz.yahoo.com - July 22 at 4:22 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta biz.yahoo.com - July 21 at 6:05 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand biz.yahoo.com - July 12 at 4:25 PM
	22nd Century to begin cannabis research at new medical campus labs www.bizjournals.com - May 12 at 2:40 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit biz.yahoo.com - May 6 at 5:55 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders biz.yahoo.com - April 15 at 3:05 PM
	GLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag www.rttnews.com - March 17 at 2:04 AM

Cleveland BioLabs (NASDAQ:CBLI) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Cleveland BioLabs (NASDAQ:CBLI) Income Statement, Balance Sheet and Cash Flow Statement

Cleveland BioLabs (NASDAQ CBLI) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff